We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ThromboGenics Appoints Dominique Vanfleteren as New CFO
News

ThromboGenics Appoints Dominique Vanfleteren as New CFO

ThromboGenics Appoints Dominique Vanfleteren as New CFO
News

ThromboGenics Appoints Dominique Vanfleteren as New CFO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ThromboGenics Appoints Dominique Vanfleteren as New CFO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ThromboGenics NV has announced the appointment of Dominique Vanfleteren as its new Chief Financial Officer (CFO) with immediate effect.

Dominique Vanfleteren has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies.

Before joining ThromboGenics, Dominique spent 12 years at UCB, a global biopharmaceutical company, where he held a number of international managerial finance positions, the latest being the CFO of UCB’s Asia Pacific Operations, operating from Brussels and Shanghai.

Prior to joining UCB, Dominique worked for GSK during 16 years. He held a number of senior finance positions in Brussels and London, his latest being Finance Director of GSK’s Diversified Healthcare Services Europe.

Dr Patrik De Haes, Chief Executive Officer of Thrombogenics, said: “I am delighted to welcome Dominique Vanfleteren to Thrombogenics as our new CFO. Dominique is bringing significant financial experience from within the biopharmaceutical industry and I am confident that he will prove a great addition to our senior management team as we look to execute our strategy as announced in mid-2014.”

Commenting on his appointment, Dominique Vanfleteren said: “I am very pleased to be joining ThromboGenics and excited to be able to contribute to the Company’s future success based on the further development of JETREA®, as well as on its broader strategy of developing innovative medicines for the treatment of ophthalmic diseases focused on diabetic retinopathy.”

Advertisement